Topic: Pfizer Inc.

Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque Psoriasis

Drugs.com - 488 days ago
Results Presented at the Annual Meeting of the European Academy of Dermatology and Venereology in Gothenburg, Sweden NEW YORK, Oct. 7 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced that data from a Phase 2 efficacy and safety study of tasocitinib (proposed ...